how many americans take glp-1 drugs 1 in 8 is now taking a medication. Yet for patients, the conversation still begins and ends with weight loss. The future of GLP-1 therapy lies in comprehensive protocols how many americans are on
Description
N Engl J Med 2016;375:183444
Over the next decade, several longer-acting versions were developed, including: Victoza (liraglutide) approved in 2010 Bydureon approved in 2012 Trulicity approved in 2014 During this period the medications were primarily prescribed for diabetes , and awareness outside medical circles was relatively limited
These drugs are created at pharmacies, where pharmacists combine different drugs and additives
Increasingly, reports suggest a possible association between GLP-1 RA use and enhanced fertility outcomes, particularly in women with obesity or polycystic ovary syndrome (PCOS)
